Average daily ischemic and bleeding risk following acute coronary syndrome: Insights from the FORCE-ACS registry.

IF 8.2 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Jaouad Azzahhafi, Dean R P P Chan Pin Yin, Niels M R van der Sangen, Wout W A van den Broek, Shabiga Sivanesan, Qiu Ying F van de Pol, Ronald J Walhout, Melvyn Tjon Joe Gin, Ron Pisters, Deborah M Nicastia, Jorina Langerveld, Georgios J Vlachojannis, Rutger J van Bommel, Yolande Appelman, José P S Henriques, Wouter J Kikkert, Jurriën M Ten Berg
{"title":"Average daily ischemic and bleeding risk following acute coronary syndrome: Insights from the FORCE-ACS registry.","authors":"Jaouad Azzahhafi, Dean R P P Chan Pin Yin, Niels M R van der Sangen, Wout W A van den Broek, Shabiga Sivanesan, Qiu Ying F van de Pol, Ronald J Walhout, Melvyn Tjon Joe Gin, Ron Pisters, Deborah M Nicastia, Jorina Langerveld, Georgios J Vlachojannis, Rutger J van Bommel, Yolande Appelman, José P S Henriques, Wouter J Kikkert, Jurriën M Ten Berg","doi":"10.1093/ehjcvp/pvag084","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>To characterize ischemic and bleeding events and compare the average daily ischemic rate (ADIR) and average daily bleeding rate (ADBR) during three years post-ACS.</p><p><strong>Methods and results: </strong>Data were derived from ACS patients enrolled in the prospective multicenter FORCE-ACS registry in nine Dutch hospitals between 2015 and 2019. ADIR and ADBR, expressed as events per 100 person-days, were calculated by dividing the total number of events by total follow-up time in the acute (day 0 to 1), subacute (day 1 to 30), late (day 30 to 365) and very late (day 365 to 1095) phase. Ischemic events comprised cardiovascular death, myocardial infarction and definite stent thrombosis; bleeding events comprised Bleeding Academic Research Consortium (BARC) type 2, 3 or 5 bleeding. The Wilcoxon signed rank test compared the ADIR and ADBR per phase.During three years, 929 ischemic events occurred in 808 patients (16.1%) and 1,694 bleeding events in 1,177 patients (23.4%). The ADBR was higher than ADIR in the acute (1.41 vs 0.68) and late phase (0.04 vs 0.02). No significant difference was observed in the subacute (0.23 vs 0.13) and very late phase. Overall, the ADBR exceeded the ADIR (0.03 vs 0.02), with the highest difference during the first year.</p><p><strong>Conclusions: </strong>Ischemic and bleeding events are most prevalent in the first 30 days post-ACS. Both ADIR and ADBR decrease over time, with the excess of ADBR over ADIR being most pronounced during the first year of follow-up.</p>","PeriodicalId":11982,"journal":{"name":"European Heart Journal - Cardiovascular Pharmacotherapy","volume":" ","pages":""},"PeriodicalIF":8.2000,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Heart Journal - Cardiovascular Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ehjcvp/pvag084","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Aims: To characterize ischemic and bleeding events and compare the average daily ischemic rate (ADIR) and average daily bleeding rate (ADBR) during three years post-ACS.

Methods and results: Data were derived from ACS patients enrolled in the prospective multicenter FORCE-ACS registry in nine Dutch hospitals between 2015 and 2019. ADIR and ADBR, expressed as events per 100 person-days, were calculated by dividing the total number of events by total follow-up time in the acute (day 0 to 1), subacute (day 1 to 30), late (day 30 to 365) and very late (day 365 to 1095) phase. Ischemic events comprised cardiovascular death, myocardial infarction and definite stent thrombosis; bleeding events comprised Bleeding Academic Research Consortium (BARC) type 2, 3 or 5 bleeding. The Wilcoxon signed rank test compared the ADIR and ADBR per phase.During three years, 929 ischemic events occurred in 808 patients (16.1%) and 1,694 bleeding events in 1,177 patients (23.4%). The ADBR was higher than ADIR in the acute (1.41 vs 0.68) and late phase (0.04 vs 0.02). No significant difference was observed in the subacute (0.23 vs 0.13) and very late phase. Overall, the ADBR exceeded the ADIR (0.03 vs 0.02), with the highest difference during the first year.

Conclusions: Ischemic and bleeding events are most prevalent in the first 30 days post-ACS. Both ADIR and ADBR decrease over time, with the excess of ADBR over ADIR being most pronounced during the first year of follow-up.

急性冠脉综合征后的平均每日缺血和出血风险:来自FORCE-ACS注册表的见解
目的:描述acs后3年的缺血和出血事件特征,并比较平均每日缺血率(ADIR)和平均每日出血率(ADBR)。方法和结果:数据来自2015年至2019年期间在荷兰9家医院的前瞻性多中心FORCE-ACS注册中心登记的ACS患者。ADIR和ADBR以每100人天的事件数表示,通过将事件总数除以急性期(0 - 1天)、亚急性期(1 - 30天)、晚期(30 - 365天)和极晚期(365 - 1095天)的总随访时间来计算。缺血性事件包括心血管死亡、心肌梗死和明确的支架血栓形成;出血事件包括出血学术研究联盟(BARC) 2、3或5型出血。采用Wilcoxon符号秩检验比较每个阶段的adr和ADBR。三年间,808例患者发生了929例缺血事件(16.1%),1177例患者发生了1694例出血事件(23.4%)。急性期(1.41 vs 0.68)和晚期(0.04 vs 0.02) ADBR高于ADIR。亚急性期(0.23 vs 0.13)和极晚期无显著差异。总体而言,ADBR超过ADIR (0.03 vs 0.02),第一年差异最大。结论:缺血性和出血事件在acs后的前30天最为常见。ADIR和ADBR均随时间下降,ADBR超过ADIR在随访的第一年最为明显。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
European Heart Journal - Cardiovascular Pharmacotherapy
European Heart Journal - Cardiovascular Pharmacotherapy Medicine-Cardiology and Cardiovascular Medicine
CiteScore
10.10
自引率
14.10%
发文量
65
期刊介绍: The European Heart Journal - Cardiovascular Pharmacotherapy (EHJ-CVP) is an international, peer-reviewed journal published in English, specifically dedicated to clinical cardiovascular pharmacology. EHJ-CVP publishes original articles focusing on clinical research involving both new and established drugs and methods, along with meta-analyses and topical reviews. The journal's primary aim is to enhance the pharmacological treatment of patients with cardiovascular disease by interpreting and integrating new scientific developments in this field. While the emphasis is on clinical topics, EHJ-CVP also considers basic research articles from fields such as physiology and molecular biology that contribute to the understanding of cardiovascular drug therapy. These may include articles related to new drug development and evaluation, the physiological and pharmacological basis of drug action, metabolism, drug interactions, and side effects.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书